CR9211A - Composiciones que comprenden una epotilona y metodos de produccion - Google Patents

Composiciones que comprenden una epotilona y metodos de produccion

Info

Publication number
CR9211A
CR9211A CR9211A CR9211A CR9211A CR 9211 A CR9211 A CR 9211A CR 9211 A CR9211 A CR 9211A CR 9211 A CR9211 A CR 9211A CR 9211 A CR9211 A CR 9211A
Authority
CR
Costa Rica
Prior art keywords
epotilone
compositions
production methods
methods
epothilones
Prior art date
Application number
CR9211A
Other languages
English (en)
Inventor
Reer Olaf
Renz Matthias
Sachse Andreas
Sprenger Claudia
Thomsen Jens
Uffrecht Anka
Original Assignee
Bayer Schering Parma Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Parma Aktiengellschaft filed Critical Bayer Schering Parma Aktiengellschaft
Publication of CR9211A publication Critical patent/CR9211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

La presente invencion se refiere a metodos para producir formulaciones farmaceuticas de epotilonas apropiadas para administrar por via parenteral, tal como por via intravenosa.
CR9211A 2004-12-23 2007-06-26 Composiciones que comprenden una epotilona y metodos de produccion CR9211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090516A EP1674098A1 (en) 2004-12-23 2004-12-23 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water

Publications (1)

Publication Number Publication Date
CR9211A true CR9211A (es) 2007-11-23

Family

ID=34928859

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9211A CR9211A (es) 2004-12-23 2007-06-26 Composiciones que comprenden una epotilona y metodos de produccion

Country Status (22)

Country Link
EP (3) EP1674098A1 (es)
JP (1) JP2008525362A (es)
KR (1) KR20070088802A (es)
CN (1) CN101137364B (es)
AR (1) AR052346A1 (es)
AU (1) AU2005318353B2 (es)
BR (1) BRPI0519441A2 (es)
CA (1) CA2591997A1 (es)
CR (1) CR9211A (es)
GT (1) GT200500386A (es)
IL (1) IL183937A0 (es)
MX (1) MX2007007780A (es)
NO (1) NO20073772L (es)
NZ (1) NZ555989A (es)
PA (1) PA8657901A1 (es)
PE (2) PE20100240A1 (es)
RU (1) RU2416407C2 (es)
SG (1) SG161207A1 (es)
TW (1) TWI367758B (es)
UA (1) UA88182C2 (es)
UY (1) UY29307A1 (es)
WO (1) WO2006066949A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
SMT202000447T1 (it) 2011-04-28 2020-09-10 Oncopeptides Ab Preparazione liofilizzata di dipeptidi citotossici
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
CN121568695A (zh) * 2024-04-12 2026-02-24 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19728914A1 (de) 1997-07-07 1999-01-14 Basf Ag Metallisch gefärbte Polyamide
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
HUP0101564A3 (en) * 1998-02-05 2002-06-28 Novartis Ag Compositions containing epothilone
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
SE517641C2 (sv) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
SK11852001A3 (sk) 1999-02-18 2002-04-04 Schering Aktiengesellschaft Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
IL144590A0 (en) * 1999-03-29 2002-05-23 Bristol Myers Squibb Co A process for the preparation of epothilone derivatives
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
AU2001243372A1 (en) 2000-03-01 2001-09-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001092255A2 (en) 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2416159A1 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
AU2001283275A1 (en) 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2005500974A (ja) 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
DE50111753D1 (de) 2000-10-16 2007-02-08 R & D Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
KR100851719B1 (ko) * 2001-01-25 2008-08-11 브리스톨-마이어스스퀴브컴파니 암 치료용 에포틸론 유사체의 투여 방법
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
US7091193B2 (en) * 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs

Also Published As

Publication number Publication date
AU2005318353A1 (en) 2006-06-29
CA2591997A1 (en) 2006-06-29
SG161207A1 (en) 2010-05-27
UA88182C2 (ru) 2009-09-25
CN101137364A (zh) 2008-03-05
GT200500386A (es) 2006-08-01
PE20060839A1 (es) 2006-09-15
NZ555989A (en) 2010-12-24
EP1674098A1 (en) 2006-06-28
EP2371365A1 (en) 2011-10-05
RU2416407C2 (ru) 2011-04-20
PA8657901A1 (es) 2007-01-17
CN101137364B (zh) 2011-11-16
TW200635586A (en) 2006-10-16
BRPI0519441A2 (pt) 2009-01-20
UY29307A1 (es) 2006-07-31
AR052346A1 (es) 2007-03-14
NO20073772L (no) 2007-09-21
PE20100240A1 (es) 2010-05-02
TWI367758B (en) 2012-07-11
EP1827428A1 (en) 2007-09-05
JP2008525362A (ja) 2008-07-17
HK1114015A1 (en) 2008-10-24
MX2007007780A (es) 2007-08-14
KR20070088802A (ko) 2007-08-29
RU2007128068A (ru) 2009-01-27
WO2006066949A1 (en) 2006-06-29
AU2005318353B2 (en) 2011-09-29
IL183937A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
HN2008000792A (es) Compuesto de cinamida biciclico
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
BR112012011328A2 (pt) inibidores de akt
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
CR9211A (es) Composiciones que comprenden una epotilona y metodos de produccion
EA200701462A1 (ru) Распадающаяся при пероральном приёме композиция оланзапина или донепезила
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
GT200600144AA (es) 1h-quinazolin-2,4-dionas (solicitud fraccionaria, derivada de la solicitud de patente de invencion pi-2006-00144)
BRPI0408848A8 (pt) Composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
ATE552832T1 (de) Antidepressivum-propharmaka
CR9231A (es) Pirroles sustituidos, composiciones que los contienen, procesos de fabricacion y utilizacion
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento
PE20091098A1 (es) Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina
DOP2005000274A (es) Composicion que comprende una epotilona y metodos para producir dicha composicion.
CU20070147A7 (es) Composiciones que comprenden una epotilona y métodos para producir dicha composición
TN2010000243A1 (en) Pharmaceutical composition
AR068374A1 (es) Nuevas composiciones farmaceuticas del complejo lamivudina beta - ciclodextrina
CR9115A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
GT200800254A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)